Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Amigo

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Leukemia|May 7, 2015
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registryT Bernal, P Martínez-Camblor, J Sánchez-García, et al.
Leukemia Research|August 21, 2014
Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patientsM Díez Campelo, M Sánchez-Barba, V Gómez-García de Soria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapyPau Montesinos, José D González, José González, et al.
British Journal of Haematology|May 26, 2018
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemiaAna M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, et al.
Leukemia & Lymphoma|June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patientsBlanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
Cancer|June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Annals of Hematology|June 17, 2024
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?E U Suárez, B Boluda, E Lavilla, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Cancer|April 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registryJuan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil, et al.
Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Leukemia|May 7, 2015
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registryT Bernal, P Martínez-Camblor, J Sánchez-García, et al.
Leukemia Research|August 21, 2014
Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patientsM Díez Campelo, M Sánchez-Barba, V Gómez-García de Soria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapyPau Montesinos, José D González, José González, et al.
British Journal of Haematology|May 26, 2018
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemiaAna M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, et al.
Leukemia & Lymphoma|June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patientsBlanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
Cancer|June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Annals of Hematology|June 17, 2024
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?E U Suárez, B Boluda, E Lavilla, et al.
Leukemia|October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Cancer|April 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registryJuan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil, et al.
Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.
Pageof 8